ArticleBMJ neurology open2025
Exploring rituximab for the treatment of refractory myasthenia gravis: a single-centre experience.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myasthenia gravis (MG) is a rare autoimmune disorder that affects neuromuscular transmission, leading to muscle weakness. While most patients respond to standard treatments, approximately 15% remain refractory, prompting interest in alternative therapies. This study examined the use of rituximab in patients with refractory MG at a single centre in Latvia, intending to broaden discussions on treatment strategies. Materials and methods: The prospective cohort study was conducted at Pauls Stradiņš Clinical University Hospital from November 2022 to March 2024. Refractory MG was defined as failure to achieve adequate disease control despite standard immunosuppressive therapy, including patients with persistent symptoms, recurrent crises or intolerance to medications. Myasthenia Gravis Composite Score (MGCS), Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Quality of Life (scores at baseline and monthly for 6 months) were completed. Glucocorticosteroid doses were also recorded. Data were analysed using descriptive statistics and Wilcoxon signed-rank test, considering p<0.05 significant. Results: 98 patients with MG were evaluated to identify treatment-refractory cases. A total of nine patients with refractory MG (median disease duration 7 years, range 1-12) were included and received a single low dose of rituximab. Among the nine patients treated, seven were acetylcholine receptor-positive and two were muscle-specific kinase antibody-seropositive. 6 months after treatment, the median MGCS decreased from 11.5 (IQR 7.3-17.8) to 7.5 (IQR 3.8-8.0) (p=0.025). The median daily corticosteroid dose decreased from 15.0 mg (IQR 10.0-20.9) to 8.5 mg (IQR 5.0-12.5) (p=0.036). There were no exacerbations of MG or significant adverse reactions. Conclusions: Our findings suggest that rituximab may be a promising treatment option for refractory MG. The notable clinical benefits and safety profile make rituximab a valuable addition to this challenging autoimmune disorder treatment options. Further research is needed to refine patient selection and dosing for optimal treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.